KROS Keros Therapeutics Inc

Price (delayed)

$11.63

Market cap

$230.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.22

Enterprise value

-$12.74M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 22

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the ...

Highlights
The debt has contracted by 12% YoY and by 3.6% from the previous quarter
The company's net income rose by 2.3% QoQ
The quick ratio has grown by 4.6% YoY but it has contracted by 3.3% from the previous quarter
The revenue has dropped by 94% year-on-year and by 55% since the previous quarter
The gross profit has plunged by 94% YoY and by 55% from the previous quarter

Key stats

What are the main financial stats of KROS

KROS stock price

How has the Keros Therapeutics stock price performed over time
Intraday
-0.85%
1 week
8.29%
1 month
5.44%
1 year
-25.88%
YTD
-42.88%
QTD
8.69%

Financial performance

How have Keros Therapeutics's revenue and profit performed over time
Revenue
$15.01M
Gross profit
$15.01M
Operating income
-$101.47M
Net income
-$83.16M
Gross margin
100%
Net margin
-553.9%
The net margin has plunged by 116% from the previous quarter
The operating margin has dropped by 103% since the previous quarter
The revenue has dropped by 94% year-on-year and by 55% since the previous quarter
The gross profit has plunged by 94% YoY and by 55% from the previous quarter

Price vs fundamentals

How does KROS's price correlate with its fundamentals

Growth

What is Keros Therapeutics's growth rate over time

Valuation

What is Keros Therapeutics stock price valuation
P/E
N/A
P/B
0.88
P/S
15.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.85
KROS's EPS is down by 27% since the previous quarter
The price to book (P/B) is 71% lower than the 5-year quarterly average of 3.1 and 19% lower than the last 4 quarters average of 1.1
KROS's equity has dropped by 63% year-on-year and by 8% since the previous quarter
KROS's P/S is 134% above its last 4 quarters average of 6.6 but 100% below its 5-year quarterly average of 9127.8
The revenue has dropped by 94% year-on-year and by 55% since the previous quarter

Efficiency

How efficient is Keros Therapeutics business performance
KROS's return on sales has dropped by 111% since the previous quarter
The ROE has contracted by 26% from the previous quarter
The company's return on assets fell by 25% QoQ
The ROIC has contracted by 6% from the previous quarter

Dividends

What is KROS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KROS.

Financial health

How did Keros Therapeutics financials performed over time
KROS's total assets has shrunk by 62% YoY and by 8% QoQ
The total liabilities has declined by 50% year-on-year and by 5% since the previous quarter
The debt is 94% less than the equity
KROS's debt to equity has soared by 100% year-on-year
KROS's equity has dropped by 63% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.